Cartalax
- Category
- Bioregulators
- Administration routes
- InjectableOral
- Regulatory status
- Not FDA-approved
What it is
A synthetic tripeptide (Ala-Glu-Asp) marketed for joint and cartilage support, said to regulate genes in chondrocytes and osteoblasts tied to cartilage repair and bone formation. The case is mostly mechanistic and speculative, drawn from cell studies rather than human trials, so joint benefit claims remain unproven in people. There is essentially no human safety data, and supply is largely unregulated research-grade product. Not an approved drug in the US.
Read Full recordStudied uses & evidence
Studied uses(6)
Chondrogenic gene activation
SpeculativeAn indexed 2023 study found increased chondrogenic markers in aging human MSC cultures; clinical benefit remains unproven (PMID 37782646).
Anti-apoptotic effects in connective tissue
LowReduced apoptosis markers in human skin fibroblasts and rat kidney explants, not cartilage.
Extracellular matrix protection
LowSingle in vitro study found MMP-9 suppression in aging skin fibroblasts, not cartilage.
Evidence limits
- Evidence Level
- Preclinical
LIMITED. Evidence is primarily preclinical (in vitro cell culture studies). No large-scale randomized controlled trials in Western literature. Key evidence: (1) In vitro: AED at 200 ng/ml activates chondrogenic differentiation markers in aging human MSCs (Myakisheva et al., 2023). (2) In vitro: AED inhibits MMP-9 and caspase-3 while upregulating Ki-67 and CD98hc in aging skin fibroblasts (Linkova et al., 2016). (3) Molecular modeling: AED binds ACCT DNA sequence, providing mechanistic basis (Khavinson et al., 2016). (4) Systematic review confirms short peptides including AED regulate gene expression via DNA-peptide interactions (Khavinson et al., 2021). Russian clinical experience reports benefits in musculoskeletal conditions but lacks peer-reviewed controlled trial data accessible in Western databases.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(5)
Risks = level of concern: High · Moderate · Low · Theoretical
Lack of large-scale clinical safety data
HighMild injection site reactions
LowPotential allergic reactions
LowUnregulated product quality
HighUnknown long-term effects
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.